Investor Presentation
55
Investor presentation First six months of 2022
ONWARDS 6 met its primary endpoint of demonstrating non-
inferiority in reducing HbA1c compared to insulin degludec
Change from baseline (%)
Non-inferior change in HbA1c from baseline over 26 weeks
0
0.00
-0.25
-0.50
Time since randomisation (weeks)
10
18
HHH
26
26*
HHHHH
Inclusion criteria
.
.
•
-0.47%
-0.51%
•
T1D treated with basal-bolus insulin
Age ≥ 18 years, HbA1c < 10%
Endpoint:
From an overall baseline HbA1c of 7.6%, once-weekly insulin
icodec achieved a reduction in estimated HbA1c of -0.47%
compared to -0.51% for insulin degludec in a T1D population
Estimated treatment difference: 0.05%
Safety:
A statistical difference in the estimated rates of severe or
clinically hypoglycaemia events
-0.75
.
19.93 events for insulin icodec vs 10.37 events for insulin
degludec
Once-weekly insulin icodec Once-daily insulin degludec
Note: Overall baseline HbA1c of 7.6%
* Lines are based on observed data where the value denoted after 26-week is estimated mean value 26 derived based on multiple imputation
T1D: Type 1 diabetes
Novo NordiskⓇView entire presentation